Gimv
Gimv is a European investment company based in Antwerp, Belgium, with over 30 years of experience in private equity and venture capital. Founded in 1980, the firm focuses on a diverse range of sectors, including business-to-business services, financial services, healthcare, information technology, technology, media and entertainment, telecommunications, manufacturing, and life sciences. Gimv operates primarily in Belgium, France, Germany, the Netherlands, and Switzerland, managing approximately 1.8 billion EUR in investments across 85 portfolio companies. These companies collectively generate over 6 billion EUR in turnover and employ more than 28,000 professionals.
Fire1
Venture Round in 2025
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Fire1
Venture Round in 2023
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
SynOx Therapeutics
Series A in 2020
SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.